It is a bad thing that First Manhattan is involved like this. Vvus is circling the wagons as Tim Morris basically said the company is pleased with the way things are going and have a board of " highly qualified and experienced" proven business leaders and experts in the biopharm industry. Also, there are far too many negatives that naturally would dissuade ANY major pharmaceutical company from tendering an offer.
I totally disagree. There are lots of positives that BP would jump at the chance to handle and I think a lot of the cost of sales and the REM could likely be somewhat absorbed by a built in force that they already have. VVUS has to take all the cost right off the top. The right to advertise in a few months is huge in my opinion. VVUS took the straight and narrow approach on that which maybe they should be commended for but their window of opportunity to make money is slipping. STENDRA's window remains shut as years slip away. BP could do something with that opportunity